Aurion Biotech's Commercial Launch of Vyznova: A New Hope for Bullous Keratopathy
Aurion Biotech Launches Vyznova in Japan
Aurion Biotech has officially announced the commercial introduction of neltependocel (Vyznova) in Japan. This treatment targets bullous keratopathy of the cornea, a condition that can severely impair vision and cause debilitating pain.
The Impact of Bullous Keratopathy
Bullous keratopathy represents a sight-threatening issue impacting the endothelial cells of the cornea. As fluid builds up and forms blisters, patients may suffer from various symptoms, including blurred vision and discomfort. If untreated, there is a risk of blindness.
Importance of the Launch
- Prior to Vyznova, the main treatment was corneal transplantation, which faced significant challenges due to the shortage of donor corneas in Japan.
- Greg Kunst, CEO of Aurion Biotech, remarked on the significance of this launch for patients worldwide suffering from corneal diseases.
Dr. Shigeru Kinoshita at Kyoto Prefecture University of Medicine pioneered the research on using neltependocel. His dedication led to the effective adoption of this breakthrough in regenerative medicine.
Aurion's recent accolades in the U.S. include receiving Breakthrough Therapy Designation and Regenerative Medicine Advanced Therapy Designation for its other cell therapy candidate, AURN001, indicating the company's commitment to advancing ophthalmic treatments.
Disclaimer: The information provided on this site is for informational purposes only and is not intended as medical advice. We are not responsible for any actions taken based on the content of this site. Always consult a qualified healthcare provider for medical advice, diagnosis, and treatment. We source our news from reputable sources and provide links to the original articles. We do not endorse or assume responsibility for the accuracy of the information contained in external sources.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.